

Peter Nickerson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5933748/publications.pdf>

Version: 2024-02-01

144
papers

13,713
citations

31976

53
h-index

21540

114
g-index

150
all docs

150
docs citations

150
times ranked

8470
citing authors

#	ARTICLE	IF	CITATIONS
1	The Banff 97 working classification of renal allograft pathology. <i>Kidney International</i> , 1999, 55, 713-723.	5.2	2,817
2	Evolution and Clinical Pathologic Correlations of De Novo Donor-Specific HLA Antibody Post Kidney Transplant. <i>American Journal of Transplantation</i> , 2012, 12, 1157-1167.	4.7	817
3	Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation. <i>Transplantation</i> , 2013, 95, 19-47.	1.0	679
4	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cellâ€ and antibody-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2318-2331.	4.7	437
5	Pre-Transplant Assessment of Donor-Reactive, HLA-Specific Antibodies in Renal Transplantation: Contraindication vs. Risk. <i>American Journal of Transplantation</i> , 2003, 3, 1488-1500.	4.7	319
6	Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. <i>Kidney International</i> , 2004, 65, 323-332.	5.2	304
7	Class II HLA Epitope Matchingâ€A Strategy to Minimize De Novo Donor-Specific Antibody Development and Improve Outcomes. <i>American Journal of Transplantation</i> , 2013, 13, 3114-3122.	4.7	298
8	Rates and Determinants of Progression to Graft Failure in Kidney Allograft Recipients With De Novo Donor-Specific Antibody. <i>American Journal of Transplantation</i> , 2015, 15, 2921-2930.	4.7	287
9	Proteomic-Based Detection of Urine Proteins Associated with Acute Renal Allograft Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 219-227.	6.1	281
10	Neointimal and Tubulointerstitial Infiltration by Recipient Mesenchymal Cells in Chronic Renal-Allograft Rejection. <i>New England Journal of Medicine</i> , 2001, 345, 93-97.	27.0	259
11	The Th1/Th2 paradigm and the allograft response. <i>Current Opinion in Immunology</i> , 1996, 8, 688-693.	5.5	251
12	Cytokines and the Th1/Th2 paradigm in transplantation. <i>Current Opinion in Immunology</i> , 1994, 6, 757-764.	5.5	233
13	SLEEP APNOEA PATIENTS HAVE MORE AUTOMOBILE ACCIDENTS. <i>Lancet, The</i> , 1987, 330, 447.	13.7	216
14	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. <i>American Journal of Transplantation</i> , 2018, 18, 1604-1614.	4.7	205
15	Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3353-3362.	6.1	204
16	Proteomic-Based Identification of Cleaved Urinary Î2-microglobulin as a Potential Marker for Acute Tubular Injury in Renal Allografts. <i>American Journal of Transplantation</i> , 2005, 5, 729-738.	4.7	199
17	Flow Cytometric Crossmatching in Primary Renal Transplant Recipients with a Negative Anti-Human Globulin Enhanced Cytotoxicity Crossmatch. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2807-2814.	6.1	190
18	Mass Spectrometryâ€Based Proteomic Analysis of Urine in Acute Kidney Injury Following Cardiopulmonary Bypass: A Nested Case-Control Study. <i>American Journal of Kidney Diseases</i> , 2009, 53, 584-595.	1.9	176

#	ARTICLE	IF	CITATIONS
19	Computerized Image Analysis of Sirius Redâ€“Stained Renal Allograft Biopsies as a Surrogate Marker to Predict Long-Term Allograft Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1662-1668.	6.1	175
20	Adverse Outcomes of Tacrolimus Withdrawal in Immuneâ€“Quiescent Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3114-3122.	6.1	172
21	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. <i>Transplantation</i> , 2020, 104, 911-922.	1.0	172
22	The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival. <i>American Journal of Transplantation</i> , 2015, 15, 2197-2202.	4.7	143
23	HLA-DR/DQ molecular mismatch: A prognostic biomarker for primary alloimmunity. <i>American Journal of Transplantation</i> , 2019, 19, 1708-1719.	4.7	130
24	IL-2 knockout recipient mice reject islet cell allografts. <i>Journal of Immunology</i> , 1995, 155, 489-98.	0.8	125
25	Clinical Rejection Is Distinguished from Subclinical Rejection by Increased Infiltration by a Population of Activated Macrophages. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1582-1589.	6.1	122
26	Non-Complementâ€“Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 615-625.	6.1	116
27	Understanding Medication Nonadherence after Kidney Transplant. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2290-2301.	6.1	114
28	Evolution of HLA Antibody Detection: Technology Emulating Biology. <i>Immunologic Research</i> , 2004, 29, 041-054.	2.9	101
29	Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. <i>Transplantation</i> , 2003, 76, 1498-1502.	1.0	99
30	MANIPULATION OF CYTOKINE NETWORKS IN TRANSPLANTATION. <i>Transplantation</i> , 1997, 63, 489-494.	1.0	97
31	The Use of Immunoglobulin Therapy for Patients Undergoing Solid Organ Transplantation: An Evidence-Based Practice Guideline. <i>Transfusion Medicine Reviews</i> , 2010, 24, S7-S27.	2.0	96
32	PIRs mediate innate myeloid cell memory to nonself MHC molecules. <i>Science</i> , 2020, 368, 1122-1127.	12.6	92
33	Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. <i>Journal of Immunology</i> , 1993, 150, 1093-104.	0.8	92
34	The Role of Cytokine Gene Polymorphisms in Determining Disease Susceptibility and Phenotype in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 1134-1142.	0.4	90
35	Detection of Subclinical Tubular Injury After Renal Transplantation: Comparison of Urine Protein Analysis With Allograft Histopathology. <i>Transplantation</i> , 2007, 84, 104-112.	1.0	85
36	Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. <i>Journal of Immunology</i> , 1995, 155, 1165-74.	0.8	81

#	ARTICLE	IF	CITATIONS
37	A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity. Transplantation, 2018, 102, 1338-1343.	1.0	79
38	Effect of Increasing Baseline Immunosuppression on the Prevalence of Clinical and Subclinical Rejection. Journal of the American Society of Nephrology: JASN, 1999, 10, 1801-1805.	6.1	79
39	Serum Creatinine Measurement Immediately After Cardiac Surgery and Prediction of Acute Kidney Injury. American Journal of Kidney Diseases, 2012, 59, 196-201.	1.9	73
40	Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. American Journal of Transplantation, 2017, 17, 703-711.	4.7	70
41	Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. American Journal of Transplantation, 2020, 20, 2652-2668.	4.7	70
42	Validation of Urinary CXCL10 As a Marker of Borderline, Subclinical, and Clinical Tubulitis. Transplantation, 2011, 92, 878-882.	1.0	68
43	Reproducibility of the Banff schema in reporting protocol biopsies of stable renal allografts. Nephrology Dialysis Transplantation, 2002, 17, 1081-1084.	0.7	67
44	Leukocyte Reduction of Red Blood Cell Transfusions Does not Decrease Allosensitization Rates in Potential Kidney Transplant Candidates. Journal of the American Society of Nephrology: JASN, 2004, 15, 818-824.	6.1	67
45	Functional Gene Polymorphisms in Canadian Aboriginal Populations with High Rates of Tuberculosis. Journal of Infectious Diseases, 2008, 198, 1175-1179.	4.0	65
46	Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Current Opinion in Organ Transplantation, 2013, 18, 470-477.	1.6	60
47	Strategic Use of Epitope Matching to Improve Outcomes. Transplantation, 2016, 100, 2048-2052.	1.0	59
48	The Relative Importance of Cytokine Gene Polymorphisms in the Development of Early and Late Acute Rejection and Six-Month Renal Allograft Pathology. Transplantation, 2005, 79, 836-841.	1.0	58
49	Urinary Hepcidin-25 and Risk of Acute Kidney Injury Following Cardiopulmonary Bypass. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2340-2346.	4.5	58
50	Impact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: Interaction with IL-10 gene polymorphisms. Hepatology, 2007, 45, 623-630.	7.3	56
51	Prolonged islet allograft acceptance in the absence of interleukin 4 expression. Transplant Immunology, 1996, 4, 81-85.	1.2	55
52	Does subclinical rejection contribute to chronic rejection in renal transplant patients?. Clinical Transplantation, 1999, 13, 441-446.	1.6	52
53	Early Urinary CCL2 is Associated With the Later Development of Interstitial Fibrosis and Tubular Atrophy in Renal Allografts. Transplantation, 2010, 90, 394-400.	1.0	52
54	Pre-transplant AT 1 R antibodies correlate with early allograft rejection. Transplant Immunology, 2018, 46, 29-35.	1.2	49

#	ARTICLE	IF	CITATIONS
55	Worldwide variability in deceased organ donation registries. <i>Transplant International</i> , 2012, 25, 801-811.	1.6	48
56	MATCHING FOR PRIVATE OR PUBLIC HLA EPITOPES REDUCES ACUTE REJECTION EPISODES AND IMPROVES TWO-YEAR RENAL ALLOGRAFT FUNCTION. <i>Transplantation</i> , 1998, 66, 38-43.	1.0	47
57	Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2499-2508.	4.7	46
58	The Canadian Kidney Paired Donation Program. <i>Transplantation</i> , 2015, 99, 985-990.	1.0	44
59	Analysis of Biomarkers Within the Initial 2 Years Posttransplant and 5-Year Kidney Transplant Outcomes. <i>Transplantation</i> , 2018, 102, 673-680.	1.0	44
60	Housing conditions in 2 Canadian First Nations communities. <i>International Journal of Circumpolar Health</i> , 2011, 70, 141-153.	1.2	41
61	The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. <i>American Journal of Transplantation</i> , 2022, 22, 761-771.	4.7	41
62	Vitamin D in a Northern Canadian First Nation Population: Dietary Intake, Serum Concentrations and Functional Gene Polymorphisms. <i>PLoS ONE</i> , 2012, 7, e49872.	2.5	40
63	Quantitation of allograft fibrosis and chronic allograft nephropathy. <i>Pediatric Transplantation</i> , 1999, 3, 257-270.	1.0	38
64	Immune Monitoring of Kidney Allografts. <i>American Journal of Kidney Diseases</i> , 2012, 60, 629-640.	1.9	38
65	Meeting report: FDA public meeting on patient-focused drug development and medication adherence in solid organ transplant patients. <i>American Journal of Transplantation</i> , 2018, 18, 564-573.	4.7	38
66	Protocol biopsies in renal transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 1998, 7, 691-694.	2.0	36
67	Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen-matching priorities to improve transplant outcomes? An expert review and recommendations. <i>Kidney International</i> , 2021, 100, 1012-1022.	5.2	35
68	Urinary CXCL10 Chemokine Is Associated With Alloimmune and Virus Compartment-Specific Renal Allograft Inflammation. <i>Transplantation</i> , 2018, 102, 521-529.	1.0	32
69	Elevated Urinary CCL2. <i>Transplantation</i> , 2014, 98, 39-46.	1.0	31
70	Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort. <i>American Journal of Transplantation</i> , 2021, 21, 322-328.	4.7	31
71	Long-Term Medical Outcomes Among Aboriginal Living Kidney Donors. <i>Transplantation</i> , 2010, 90, 401-406.	1.0	30
72	Effect of Vitamin D Supplementation on Mycobacterium tuberculosis-Induced Innate Immune Responses in a Canadian Deni First Nations Cohort. <i>PLoS ONE</i> , 2012, 7, e40692.	2.5	30

#	ARTICLE	IF	CITATIONS
73	Increased Urinary CCL2. <i>Transplantation</i> , 2013, 95, 595-602.	1.0	29
74	What have we learned about how to prevent and treat antibody-mediated rejection in kidney transplantation?. <i>American Journal of Transplantation</i> , 2020, 20, 12-22.	4.7	29
75	The Fourth International Workshop on Clinical Transplant Tolerance. <i>American Journal of Transplantation</i> , 2021, 21, 21-31.	4.7	28
76	Six-Month Urinary CCL2 and CXCL10 Levels Predict Long-term Renal Allograft Outcome. <i>Transplantation</i> , 2016, 100, 1988-1996.	1.0	26
77	Urinary Metabolomics for Noninvasive Detection of Antibody-Mediated Rejection in Children After Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 2553-2561.	1.0	26
78	Carpe diemâ€”Time to transition from empiric to precision medicine in kidney transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 1615-1625.	4.7	25
79	Factors Associated With Progression of Interstitial Fibrosis in Renal Transplant Patients Receiving Tacrolimus and Mycophenolate Mofetil. <i>Transplantation</i> , 2009, 88, 897-903.	1.0	24
80	Proteomic characterization of serine hydrolase activity and composition in normal urine. <i>Clinical Proteomics</i> , 2013, 10, 17.	2.1	24
81	Elevated Urinary Matrix Metalloproteinase-7 Detects Underlying Renal Allograft Inflammation and Injury. <i>Transplantation</i> , 2016, 100, 648-654.	1.0	23
82	Validity and utility of urinary CXCL10/Cr immune monitoring in pediatric kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 1545-1555.	4.7	23
83	Effectiveness of T cellâ€”mediated rejection therapy: A systematic review and meta-analysis. <i>American Journal of Transplantation</i> , 2022, 22, 772-785.	4.7	23
84	Proteomics and Renal Transplantation: Searching for Novel Biomarkers and Therapeutic Targets. , 2008, 160, 65-75.		22
85	Post-transplant monitoring of renal allografts: are we there yet?. <i>Current Opinion in Immunology</i> , 2009, 21, 563-568.	5.5	22
86	Human leukocyte antigen molecular mismatch to risk stratify kidney transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 8-14.	1.6	22
87	Change in Estimated GFR and Risk of Allograft Failure in Patients Diagnosed With Late Active Antibody-mediated Rejection Following Kidney Transplantation. <i>Transplantation</i> , 2021, 105, 648-659.	1.0	22
88	Interleukin-15 gene transcripts are present in rejecting islet allografts. <i>Transplantation Proceedings</i> , 1997, 29, 1077-1078.	0.6	20
89	Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10. <i>Transplantation Direct</i> , 2016, 2, e78.	1.6	19
90	Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts. <i>American Journal of Transplantation</i> , 2019, 19, 1730-1744.	4.7	19

#	ARTICLE	IF	CITATIONS
91	INTERFERON-?? RECEPTOR SIGNALING IS NOT REQUIRED IN THE EFFECTOR PHASE OF THE ALLOIMMUNE RESPONSE1. <i>Transplantation</i> , 1998, 65, 1649-1652.	1.0	19
92	Protocol biopsies in the management of renal allograft recipients. <i>Current Opinion in Nephrology and Hypertension</i> , 2000, 9, 615-619.	2.0	18
93	Developing a tool for noninvasive monitoring of renal allografts. <i>Expert Review of Proteomics</i> , 2006, 3, 497-509.	3.0	18
94	The potential influence of KIR cluster profiles on disease patterns of Canadian Aboriginals and other indigenous peoples of the Americas. <i>European Journal of Human Genetics</i> , 2011, 19, 1276-1280.	2.8	18
95	Dietary intake of vitamin D in a northern Canadian DenÃ© First Nation community. <i>International Journal of Circumpolar Health</i> , 2013, 72, 20723.	1.2	18
96	CTLA4lg ATTENUATES ACCELERATED REJECTION (PRESENSITIZATION) IN THE MOUSE ISLET ALLOGRAFT MODEL1. <i>Transplantation</i> , 1997, 64, 172-175.	1.0	17
97	Acceptable mismatching at the class II epitope level. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 442-446.	1.6	16
98	Urinary biomarkers of renal transplant outcome. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 476-481.	1.6	16
99	The Impact of Immune Gene Polymorphisms in Kidney and Liver Transplantation. <i>Clinics in Laboratory Medicine</i> , 2008, 28, 455-468.	1.4	15
100	Evolution of renal function and urinary biomarker indicators of inflammation on serial kidney biopsies in pediatric kidney transplant recipients with and without rejection. <i>Pediatric Transplantation</i> , 2018, 22, e13202.	1.0	15
101	Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients. <i>BMJ Open</i> , 2019, 9, e024908.	1.9	15
102	Heightened Peripheral Blood Lymphocyte CD69 Expression is Neither Sensitive nor Specific as a Noninvasive Diagnostic Test for Renal Allograft Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 226-233.	6.1	14
103	Two cases of platelet transfusion refractoriness associated with antiâ€CD36. <i>Transfusion</i> , 2010, 50, 2638-2642.	1.6	14
104	Killer Immunoglobulin-Like Receptor (KIR) Centromeric-AA Haplotype Is Associated with Ethnicity and Tuberculosis Disease in a Canadian First Nations Cohort. <i>PLoS ONE</i> , 2013, 8, e67842.	2.5	14
105	Vitamin D, serum 25(OH)D, LL-37 and polymorphisms in a Canadian First Nation population with endemic tuberculosis. <i>International Journal of Circumpolar Health</i> , 2015, 74, 28952.	1.2	14
106	Prediction of Long-term Renal Allograft Outcome By Early Urinary CXCL10 Chemokine Levels. <i>Transplantation Direct</i> , 2015, 1, e31.	1.6	13
107	Technical Considerations and Confounders for Urine CXCL10 Chemokine Measurement. <i>Transplantation Direct</i> , 2020, 6, e519.	1.6	13
108	Rejection: An Integrated Response. <i>American Journal of Transplantation</i> , 2013, 13, 2239-2240.	4.7	11

#	ARTICLE	IF	CITATIONS
109	IL-2 and IL-4 double knock-out mice reject islet allografts: A role for novel T-cell growth factors?. Transplantation Proceedings, 1997, 29, 1083-1084.	0.6	10
110	Long-term allograft surveillance: the role of protocol biopsies. Current Opinion in Urology, 2001, 11, 133-137.	1.8	10
111	Biologically Variable Bypass Reduces Enzymuria After Deep Hypothermic Circulatory Arrest. Annals of Thoracic Surgery, 2006, 82, 1480-1488.	1.3	10
112	HLA-A, B, DRB1, DQA1, DQB1 alleles and haplotype frequencies in Dene and Cree cohorts in Manitoba, Canada. Human Immunology, 2017, 78, 401-411.	2.4	10
113	Early Antibody-Mediated Kidney Transplant Rejection Associated With Anti-Vimentin Antibodies: A Case Report. American Journal of Kidney Diseases, 2020, 75, 138-143.	1.9	10
114	The Routine Use of High-Resolution Immunological Screening of Recipients of Primary Deceased Donor Kidney Allografts Is Cost-Effective. Transplantation, 2006, 81, 1278-1284.	1.0	9
115	Blood donors implicated in transfusion-related acute lung injury with patient-specific HLA antibodies are more broadly sensitized to HLA antigens compared to other blood donors. Transfusion, 2013, 53, 518-525.	1.6	9
116	Donation after circulatory determination of death in western Canada: a multicentre study of donor characteristics and critical care practices. Canadian Journal of Anaesthesia, 2020, 67, 521-531.	1.6	8
117	Antibodies Beyond HLA. American Journal of Transplantation, 2013, 13, 831-832.	4.7	7
118	Begin at the Beginning to Prevent the End. Journal of the American Society of Nephrology: JASN, 2015, 26, 1483-1485.	6.1	7
119	Human leukocyte antigen mismatch and precision medicine in transplantation. Current Opinion in Organ Transplantation, 2018, 23, 500-505.	1.6	7
120	More precise donor-recipient matching: the role of eplet matching. Current Opinion in Nephrology and Hypertension, 2020, 29, 630-635.	2.0	7
121	Subclinical Antibody-Mediated Rejection. Transplantation, 2017, 101, S1-S18.	1.0	6
122	Defining the structural basis for human leukocyte antigen reactivity in clinical transplantation. Scientific Reports, 2020, 10, 18397.	3.3	6
123	Early surveillance biopsy utilization and management of pediatric renal allograft acute T cell-mediated rejection in Canadian centers: Observations from the PROBE multicenter cohort study. Pediatric Transplantation, 2021, 25, e13870.	1.0	6
124	Subclinical acute rejection: Is it a cause of chronic rejection in renal transplantation?. Transplantation Reviews, 2000, 14, 131-137.	2.9	5
125	Proteomic Portrayal of Transplant Pathologies. Journal of the American Society of Nephrology: JASN, 2009, 20, 236-238.	6.1	5
126	Effect of Time on Dialysis and Renal Transplantation on Endothelial Function. Transplantation, 2014, 98, 1060-1068.	1.0	5

#	ARTICLE	IF	CITATIONS
127	Activity-based Protein Profiling Approaches for Transplantation. <i>Transplantation</i> , 2019, 103, 1790-1798.	1.0	4
128	PROTOCOL BIOPSY PREDICTION OF LONG TERM RENAL ALLOGRAFT SURVIVAL: USING COMPUTERIZED IMAGE ANALYSIS OF SIRIUS RED STAINED FIBROSIS.. <i>Transplantation</i> , 2000, 69, S363.	1.0	3
129	A call to actionâ€”The transplant recipientâ€™s expectation of precision in transplant medicine. <i>American Journal of Transplantation</i> , 2018, 18, 2845-2846.	4.7	3
130	Hyperacute Antibody-mediated Rejection Associated With Red Blood Cell Antibodies. <i>Transplantation Direct</i> , 2019, 5, e477.	1.6	3
131	Activity-based protein profiling guided identification of urine proteinase 3 activity in subclinical rejection after renal transplantation. <i>Clinical Proteomics</i> , 2020, 17, 23.	2.1	3
132	High serum levels of interleukin-6 in renal transplant recipients with monoclonal gammopathies. <i>Transplantation</i> , 1994, 58, 382-6.	1.0	3
133	Molecular Mismatchâ€”the Renaissance of HLA in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1922-1925.	6.1	2
134	Role of HLA molecular mismatch in clinical practice. <i>Human Immunology</i> , 2022, 83, 219-224.	2.4	2
135	Detection of a single nucleotide polymorphism in the IL-6 promoter region of ancient nuclear DNA. <i>Infection, Genetics and Evolution</i> , 2005, 5, 117-122.	2.3	1
136	Proinflammatory Events and HLA Antibodies: Nothing to Sneeze At. <i>American Journal of Transplantation</i> , 2009, 9, 1971-1972.	4.7	1
137	Phospholipase A2 group XV activity during cardiopulmonary bypass surgery. <i>Clinical Biochemistry</i> , 2021, 88, 49-55.	1.9	1
138	A noninferiority design for a delayed calcineurin inhibitor substitution trial in kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 1503-1512.	4.7	1
139	Modest Improvements in Refractory Antibody-Mediated Rejection After Prolonged Treatment. <i>Kidney International Reports</i> , 2021, 6, 1397-1401.	0.8	1
140	Proteomics of Human Urine. , 2007, , 225-268.		0
141	Response to Proinflammatory Events and HLA Antibodies. <i>American Journal of Transplantation</i> , 2010, 10, 957-957.	4.7	0
142	Cytokines and Their Receptors as Therapeutic Targets. , 2001, , 81-99.		0
143	The Use of IVIG for Solid Organ Transplantation: An Evidence Based Practice Guideline. <i>Blood</i> , 2008, 112, 4666-4666.	1.4	0
144	Age and sex determine conversion from immediateâ€”release to extendedâ€”release tacrolimus in a multiâ€”center cohort of Canadian pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2021, 25, e13959.	1.0	0